Ask about this productRelated genes to: ZADH2 antibody
- Gene:
- ZADH2 NIH gene
- Name:
- zinc binding alcohol dehydrogenase domain containing 2
- Previous symbol:
- -
- Synonyms:
- MGC45594
- Chromosome:
- 18q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 2004-06-17
- Date modifiied:
- 2015-07-16
Related products to: ZADH2 antibody
Related articles to: ZADH2 antibody
- Low birth weight in newborns is of multifactorial origin (fetal, maternal, placental, and environmental factors), and in one-third of cases, the cause is of unknown origin, with high infant morbidity and mortality. The main treatment for regaining weight and height in children with low birth weight is the application of growth hormones. However, their role as a protective factor to prevent an increase in body composition and the development of metabolic diseases is still poorly understood. : A case-control study was conducted in a cohort of patients consulted at the CES Pediatric Endocrinology Clinic, Medellín, Colombia, between 2008 and 2018. We evaluated sociodemographic and clinical variables. Additionally, the identification of differential patterns of genomic methylation between cases (treated with growth hormone) and controls (without growth hormone treatment) was performed. The groups were compared using Fisher's exact test for qualitative variables and Student's -test for the difference in means in independent samples. The correlation was evaluated with the Pearson coefficient. Regarding clinical manifestations, body mass index (BMI) was higher in children who did not receive growth hormone treatment, higher doses of growth hormone treatment helped reduce body mass index (R: -0.21, and = 0.067), and the use of growth hormone was related to a decrease in triglyceride blood concentrations ( = 0.06); these results tended towards significance. Regarding genome-wide methylation patterns, the following genes were found to be hypermethylated: , and . Meanwhile, the following genes were found hypomethylated: , and . Using growth hormone as a treatment in SGA newborns helps regain weight and height. Additionally, it could be a protective factor against the increase in adolescent body composition. - Source: PubMed
Publication date: 2025/05/23
Velásquez Juan M AlfaroVásquez Trespalacios Elsa MariaUrrego RodrigoArroyave Toro María CMontilla Velásquez María Del PilarSoto Cecilia Maria DíazVélez Juan C ZuluagaJaramillo Henríquez VerónicaFlórez Jorge Emilio SalazarMonroy Fernando PPalacio Mosquera Hernando AlirioVélez Gómez SaraPelaez Sánchez Ronald Guillermo - To examine the relationship between miRNA-3679 and hepatocellular carcinoma (HCC) cell lines, and to verify the downstream target genes of miRNA-3679. - Source: PubMed
He Jing-YuZhou Xue-QinWang Wen-Tao - Peroxisomes are ubiquitous, oxidative subcellular organelles with important functions in cellular lipid metabolism and redox homeostasis. Loss of peroxisomal functions causes severe disorders with developmental and neurological abnormalities. Zebrafish are emerging as an attractive vertebrate model to study peroxisomal disorders as well as cellular lipid metabolism. Here, we combined bioinformatics analyses with molecular cell biology and reveal the first comprehensive inventory of peroxisomal proteins, which we systematically compared with those of human peroxisomes. Through bioinformatics analysis of all PTS1-carrying proteins, we demonstrate that lacks two well-known mammalian peroxisomal proteins (BAAT and ZADH2/PTGR3), but possesses a putative peroxisomal malate synthase (Mlsl) and verified differences in the presence of purine degrading enzymes. Furthermore, we revealed novel candidate peroxisomal proteins in , whose function and localisation is discussed. Our findings confirm the suitability of zebrafish as a vertebrate model for peroxisome research and open possibilities for the study of novel peroxisomal candidate proteins in zebrafish and humans. - Source: PubMed
Publication date: 2022/02/28
Kamoshita MakiKumar RechalAnteghini MarcoKunze MarkusIslinger MarkusMartins Dos Santos VítorSchrader Michael - Polo-like kinase 1 (PLK1) is an important cell cycle kinase and an attractive target for anticancer treatments. An ATP-competitive small molecular PLK1 inhibitor, volasertib, has reached phase III in clinical trials in patients with refractory acute myeloid leukemia as a combination treatment with cytarabine. However, severe side effects limited its use. The origin of the side effects is unclear and might be due to insufficient specificity of the drug. Thus, identifying potential off-targets to volasertib is important for future clinical trials and for the development of more specific drugs. In this study, we used thermal proteome profiling (TPP) to identify proteome-wide targets of volasertib. Apart from PLK1 and proteins regulated by PLK1, we identified about 200 potential volasertib off-targets. Comparison of this result with the mass-spectrometry analysis of volasertib-treated cells showed that phosphatidylinositol phosphate and prostaglandin metabolism pathways are affected by volasertib. We confirmed that PIP4K2A and ZADH2-marker proteins for these pathways-are, indeed, stabilized by volasertib. PIP4K2A, however, was not affected by another PLK1 inhibitor onvansertib, suggesting that PIP4K2A is a true off-target of volasertib. Inhibition of these proteins is known to impact both the immune response and fatty acid metabolism and could explain some of the side effects seen in volasertib-treated patients. - Source: PubMed
Goroshchuk OksanaKolosenko IrynaKunold ElenaVidarsdottir LindaPirmoradian MohammadAzimi AlirezaJafari RozbehPalm-Apergi Caroline - To carry out genome-wide copy number variations (CNVs) analysis for a boy with autism by using single nucleotide polymorphism array (SNP array). - Source: PubMed
He XuelianZhao PeiweiHuang YufengCai XiaonanBi BoLin Jun